286 related articles for article (PubMed ID: 16239385)
1. The British Society for Rheumatology biologics register.
Watson K; Symmons D; Griffiths I; Silman A
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv42-3. PubMed ID: 16239385
[TBL] [Abstract][Full Text] [Related]
2. British Society for Rheumatology Biologics Register.
Silman A; Symmons D; Scott DG; Griffiths I
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii28-9. PubMed ID: 14532144
[TBL] [Abstract][Full Text] [Related]
3. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries.
Zavada J; Dixon WG; Askling J;
Ann Rheum Dis; 2014 Mar; 73(3):628. PubMed ID: 24058015
[No Abstract] [Full Text] [Related]
4. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.
Dixon WG; Carmona L; Finckh A; Hetland ML; Kvien TK; Landewe R; Listing J; Nicola PJ; Tarp U; Zink A; Askling J
Ann Rheum Dis; 2010 Sep; 69(9):1596-602. PubMed ID: 20525843
[TBL] [Abstract][Full Text] [Related]
5. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
6. BSR Biologics Registry.
Griffiths I; Silman A; Symmons D; Scott DG
Rheumatology (Oxford); 2004 Dec; 43(12):1463-4. PubMed ID: 15328420
[No Abstract] [Full Text] [Related]
7. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
8. The Corrona US registry of rheumatic and autoimmune diseases.
Kremer JM
Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S96-S99. PubMed ID: 27762197
[TBL] [Abstract][Full Text] [Related]
9. Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.
Subesinghe S; Rutherford AI; Byng-Maddick R; Leanne Hyrich K; Benjamin Galloway J
Rheumatology (Oxford); 2018 Apr; 57(4):651-655. PubMed ID: 29340619
[TBL] [Abstract][Full Text] [Related]
10. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Bechman K; Clarke BD; Rutherford AI; Yates M; Nikiphorou E; Molokhia M; Norton S; Cope AP; Hyrich KL; Galloway JB
Rheumatology (Oxford); 2019 Oct; 58(10):1767-1776. PubMed ID: 30982886
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
12. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.
Carmona L; de la Vega M; Ranza R; Casado G; Titton DC; Descalzo MÁ; Gómez-Reino J
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-163-7. PubMed ID: 25365109
[TBL] [Abstract][Full Text] [Related]
13. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
Kay LJ; Griffiths ID;
Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
[TBL] [Abstract][Full Text] [Related]
14. GISEA: an Italian biological agents registry in rheumatology.
Lapadula G; Ferraccioli G; Ferri C; Punzi L; Trotta F;
Reumatismo; 2011 Nov; 63(3):155-64. PubMed ID: 22257916
[TBL] [Abstract][Full Text] [Related]
15. [Safety of biologic therapy - results from the German biologics register RABBIT].
Strangfeld A; Zink A
Dtsch Med Wochenschr; 2014 Sep; 139(37):1817-20. PubMed ID: 25180996
[No Abstract] [Full Text] [Related]
16. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register.
Gäwert L; Hierse F; Zink A; Strangfeld A
Rheumatology (Oxford); 2011 Jan; 50(1):152-60. PubMed ID: 20871128
[TBL] [Abstract][Full Text] [Related]
17. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Bruce ES; Kearsley-Fleet L; Watson KD; Symmons DP; Hyrich KL
Rheumatology (Oxford); 2016 Jul; 55(7):1336-7. PubMed ID: 27118877
[No Abstract] [Full Text] [Related]
18. The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register.
Matcham F; Davies R; Hotopf M; Hyrich KL; Norton S; Steer S; Galloway J
Rheumatology (Oxford); 2018 May; 57(5):835-843. PubMed ID: 29447376
[TBL] [Abstract][Full Text] [Related]
19. The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data.
Eriksson JK; Askling J; Arkema EV
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-147-9. PubMed ID: 25365105
[TBL] [Abstract][Full Text] [Related]
20. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.
Burden AD; Warren RB; Kleyn CE; McElhone K; Smith CH; Reynolds NJ; Ormerod AD; Griffiths CE;
Br J Dermatol; 2012 Mar; 166(3):545-54. PubMed ID: 22356636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
